Compare Goldman Sachs Group Inc (GS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs BIO-TECHNE Corp — how do they compare? Goldman Sachs Group Inc trades at $1,034.46 (market cap $301.22B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Goldman Sachs Group Inc is far larger — about 26.8× BIO-TECHNE Corp's market cap, and Goldman Sachs Group Inc pays the higher dividend (1.93%). Which is the better fit depends on your goals.
| GS | TECH | |
|---|---|---|
Market Cap | $301.22B | $11.24B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $72.29 |
52-Week Low | $715.95 | $43.31 |
Dividend Yield | 1.93% | 0.44% |
Enterprise Value | — | $11.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,039.61, up 0.68% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $20.98 surpassing expectations of $14.47. Revenue grew to $58.28 billion in 2025, and net income margin improved to 31.68%. Analysts maintain a consensus price target of $1,160, with 40% recommending Buy. Recent news highlights GS's role in leading high-profile IPOs, including Anthropic, signaling robust investment banking activity.
The outlook for GS is positive, driven by earnings momentum and strategic positioning in key deals. Risks include volatile cash flows, with operating cash flow negative in 2025, and reliance on capital markets activity. Investor sentiment is cautiously optimistic, supported by analyst targets above the current price, but macroeconomic shifts could impact performance.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
